Gastroparesis Research
33 total studies as of March 2, 2022
For navigation, click on the topic you are interested in below:
Introduction
DEMOGRAPHICS AND FEATURES OF IDIOPATHIC GASTROPARESIS
Parkman, H. P. et al. (2011). Clinical Features of Idiopathic Gastroparesis Vary With Sex, Body Mass, Symptom Onset, Delay in Gastric Emptying, and Gastroparesis Severity. Gastroenterology, 140(1), 101–115.e10. https://doi.org/10.1053/j.gastro.2010.10.015
The researchers obtained data from 243 idiopathic gastroparesis patients, finding a mean age of 41 with a female predominance (88%) and 46% being overweight. In 28% of patients, there was severe gastric delay with >35% of food retention following 4 hours. The most common symptoms were nausea (34%), abdominal pain (23%), and vomiting (19%) - with women experiencing more severe symptoms overall. Approximately 86% of this group almost met functional dyspepsia diagnostic criteria - most commonly, post-prandial distress syndrome.
Summary by Kimberly Czotter
"
OUTCOMES AND EPIDEMIOLOGY OF GASTROPARESIS
Ye, Y., Jiang, B., Manne, S., Moses, P. L., Almansa, C., Bennett, D., Dolin, P., & Ford, A. C. (2020). Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom. Gut, 70(4), 644–653. https://doi.org/10.1136/gutjnl-2020-321277
This cross-sectional, retrospective study aimed to understand the prevalence, incidence, characteristics, and outcomes of gastroparesis in the UK population. They found that approximately 13.8 people per 100,000 had gastroparesis in 2016 (a rise from 1.5-1.6 between 2004-2016). Most of these cases were idiopathic (39.4%) or diabetic (37.5%), and those with diabetic gastroparesis had a higher risk of mortality. Not surprisingly, following diagnosis 31.6% of patients were not offered pharmacological treatment which underpinned the researchers suggestion for further research to understand the needs of patients with gastroparesis.
Summary by Kimberly Czotter
"
GASTROPARESIS REVIEW OF UNDERSTANDING AND MANAGEMENT
Grover, M., Farrugia, G., & Stanghellini, V. (2019). Gastroparesis: a turning point in understanding and treatment. Gut, 68(12), 2238–2250. https://doi.org/10.1136/gutjnl-2019-318712
This review article discusses the clinical presentation, peidemiology, pathophysiology, physiology, pathogenesis, diagnostic considerations (symptoms, gastric emptying), treatments (prokinetics, antiemetics, neuromodulators, gastric electrical stimulation, Botulinum toxin, Pyloromyotomy), and future conclusions.
Summary by Kimberly Czotter
"
COMPARISON OF IDIOPATHIC AND DIABETIC GASTROPARESIS
Parkman, H. P. et al. (2011). Similarities and Differences Between Diabetic and Idiopathic Gastroparesis. Clinical Gastroenterology and Hepatology, 9(12), 1056–1064. https://doi.org/10.1016/j.cgh.2011.08.013
This article reviews the differences and similarities between idiopathic and diabetic gastroparesis. They analyzed 416 gastroparesis patients (254 with idiopathic, 78 type-1 diabetes, 59 with type-2 diabetes), finding they were primarily female (83%), caucasian (85%), and that obesity was more common in those with type-2 diabetes (71%) compared to those with type 1 diabetes (28%) and idiopathic (26%). They then detailed differences in symptoms, treatments, severity, hospitalization and quality of life.
Summary by Kimberly Czotter
"
GASTROPARESIS REVIEW (2020)
Sullivan, A., Temperley, L., & Ruban, A. (2020). Pathophysiology, Aetiology and Treatment of Gastroparesis. Digestive Diseases and Sciences, 65(6), 1615–1631. https://doi.org/10.1007/s10620-020-06287-2
"
This recent review of gastroparesis discusses the enteric nervous system, gut hormones, and central nervous system involvement. They detail this pathophysiology, diagnosis (motility capsules, gastric scintigraphy, breath tests), and treatments which often have poor efficacy and/or high risk. Finally, they speak to newer potential treatments like endoscope myotomy."
Summary by Kimberly Czotter
"
GASTROPARESIS REVIEW (2018)
Camilleri, M., Chedid, V., Ford, A.C. et al. (2018). Gastroparesis. Nat Rev Dis Primers 4, 41. https://doi.org/10.1038/s41572-018-0038-z
This article discusses gastroparesis and the incidence, prevalence, risk factors, symptoms, pathophysiology (neuromuscular dysfunction, neuropathy, immune system,), causes of gastroparesis (diabetes, viral, surgery), difficulties of diagnosis, diagnostic process, management, medications, and identifying and treating the underlying cause. They also touch on various novel interventions and pharmacologic agents.
Summary by Kimberly Czotter
"
Life Quality
Understanding how Gastroparesis affects the quality of life of patients.
QUALITY OF LIFE WITH GASTROPARESIS
Yu, D., Ramsey, F. V., Norton, W. F., Norton, N., Schneck, S., Gaetano, T., & Parkman, H. P. (2017). The Burdens, Concerns, and Quality of Life of Patients with Gastroparesis. Digestive Diseases and Sciences, 62(4), 879–893. https://doi.org/10.1007/s10620-017-4456-7
This study of 1423 gastroparesis patients evaluated their quality of life using the SF-36 Quality of Life Survey ad Patient Assessment of Upper GI Symptoms surveys. Patients had symptoms for 5.0 ± 8.5 years before diagnosis and noted they felt they could get access to information online that was helpful, but that most were not satisfied with available treatments. They found that there was a significantly decreased quality of life that negatively correlated to symptoms: nausea, early satiety, and upper adominal pain.
Summary by Kimberly Czotter
"
Treatment Options
GASTROPARESIS TREATMENT REVIEW
Navas, C. M., Patel, N. K., & Lacy, B. E. (2017). Gastroparesis: Medical and Therapeutic Advances. Digestive Diseases and Sciences, 62(9), 2231–2240. https://doi.org/10.1007/s10620-017-4679-7
This article reviews the pathophysiology, diagnostic process, and treatments for gastroparesis. Gastroparesis often stems from connective tissue disorders, infection, diabetes, post-surgical complications, mesenteric ischemia, or is idiopathic. The burdens of gastroparesis are significant on the patient and healthcare system, with only one medication approved for treatment - metoclopramide - which has adverse risks. Most patients are treated with off-label medications including: Domperidone, Relamorelin, Camicinal, Granisetron patch, Revexepride, Velusetrag, Aprepitant, and Tradipitant. The authors suggest the need for novel, safe, and effective treatments.
Summary by Kimberly Czotter
"
MANAGING GASTROPARESIS
Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L., & Gerson, L. (2013). Clinical Guideline: Management of Gastroparesis. American Journal of Gastroenterology, 108(1), 18–37. https://doi.org/10.1038/ajg.2012.373
This review article outlines the guidelines for treating gastroparesis patients including: definition, underlying causes, diagnostic process, exclusion criteria, differential diagnosis, management (dietary), glycemic control, medications, botox injections, gastric stimulation, surgery, and alternative medicine (acupuncture).
Summary by Kimberly Czotter
"
PATIENT DIETARY PERSPECTIVES IN GASTROPARESIS
Wytiaz, V., Homko, C., Duffy, F., Schey, R., & Parkman, H. P. (2015). Foods Provoking and Alleviating Symptoms in Gastroparesis: Patient Experiences. Digestive Diseases and Sciences, 60(4), 1052–1058. https://doi.org/10.1007/s10620-015-3651-7
This questionnaire based study gives some insight to dietary changes such as reducing fiber, fat, and meal size that reduce symptoms in gastroparesis patients. There were 45 patients (39 idiopathic gastroparesis) that noted foods that worsened their symptoms included: cabbage, oranges, orange juice, fried chicken, lettuce, tomato juice, onions, pizza, sausage, peppers, salsa, bacon, roast beef, coffee, and broccoli. These symptom-provoking foods include those that are acidic, roughage, fatty, and spicy. Foods that moderately improved their symptoms included jello, graham crackers, and saltine crackers. Food thats were tolerated included: gluten-free foods, ginger ale, clear soup, white fish, white rice, salmon, potatoes, sweet potatoes, tea, applesauce, and popsicles. Well-tolerated foods were generally sweet, starchy, salty, and bland.
Summary by Kimberly Czotter
"
USING IMMUNOMODULATION TO TREAT GASTROPARESIS
Soota, K., Kedar, A., Nikitina, Y., Arendale, E., Vedanarayanan, V., & Abell, T. L. (2016). Immunomodulation for treatment of drug and device refractory gastroparesis. Results in Immunology, 6, 11–14. https://doi.org/10.1016/j.rinim.2016.02.001
This study evaluated the treatment of 11 women with device and drug resistant gastroparesis, secondary to autoimmune dysautonomia. The patients had GAD65 autoantibodies and inflammation from a gastric biopsy and were treated for 8-12 weeks with combined methylprednisolone and mycophenolate mofetil (MM), only MM, or intravenous immunoglobulin (IVIg). Following IVIg, maximum symptom improvement occurred (vomiting, abdominal pain, bloating, and nausea).
Summary by Kimberly Czotter
"